Abstract
ELABELA (ELA) and Apelin-13 (APL-13) bind to the apelin receptor (APJ), a GPCR highly expressed in the cardiovascular system. Those are the strongest known endogenous inotropic and dominant apelinergic ligands in human heart which improve heart performance during sepsis. Apelins (APL) have been also clearly committed in improving insulin sensitivity and glucose handling, including in the heart. The purpose of this study was to establish the metabolic profile and the impact of APL infusion in an experimental model of rat septic shock.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
